09.01.05
Phytomedics Inc., Dayton, NJ, a biopharmaceutical company merging healthcare and plant biotechnology, has become the exclusive licensee of U.S. patent #5,905,089, titled “Use of sesquiterpene lactones for treatment of severe inflammatory disorders.” Researchers at the Pennington Biomedical Research Center in Baton Rouge, LA, and Louisiana State University, discovered and documented the powerful anti-inflammatory properties of sesquiterpene lactones.